413 related articles for article (PubMed ID: 31449983)
1. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
Dong R; Ji J; Liu H; He X
Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
[TBL] [Abstract][Full Text] [Related]
3. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
Montemurro F; Ellis P; Anton A; Wuerstlein R; Delaloge S; Bonneterre J; Quenel-Tueux N; Linn SC; Irahara N; Donica M; Lindegger N; Barrios CH
Eur J Cancer; 2019 Mar; 109():92-102. PubMed ID: 30708264
[TBL] [Abstract][Full Text] [Related]
4. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
[TBL] [Abstract][Full Text] [Related]
5. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.
Lyseng-Williamson KA
Drugs; 2020 Nov; 80(16):1723-1730. PubMed ID: 32996066
[TBL] [Abstract][Full Text] [Related]
7. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
Montemurro F; Delaloge S; Barrios CH; Wuerstlein R; Anton A; Brain E; Hatschek T; Kelly CM; Peña-Murillo C; Yilmaz M; Donica M; Ellis P
Ann Oncol; 2020 Oct; 31(10):1350-1358. PubMed ID: 32634611
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
Hunter FW; Barker HR; Lipert B; Rothé F; Gebhart G; Piccart-Gebhart MJ; Sotiriou C; Jamieson SMF
Br J Cancer; 2020 Mar; 122(5):603-612. PubMed ID: 31839676
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
[TBL] [Abstract][Full Text] [Related]
11. T-DM1 for residual, invasive, HER2-positive breast cancer.
Burki TK
Lancet Oncol; 2019 Jan; 20(1):e13. PubMed ID: 30555022
[No Abstract] [Full Text] [Related]
12. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
[No Abstract] [Full Text] [Related]
13. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
14. Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study.
Yazaki S; Hashimoto J; Ogita S; Nakano E; Suzuki K; Yamauchi T
Anticancer Drugs; 2020 Oct; 31(9):973-978. PubMed ID: 32868644
[TBL] [Abstract][Full Text] [Related]
15. Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine.
Hopkins AM; Rowland A; Logan JM; Sorich MJ
Breast; 2019 Aug; 46():90-94. PubMed ID: 31170589
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
Mills MN; Walker C; Thawani C; Naz A; Figura NB; Kushchayev S; Etame A; Yu HM; Robinson TJ; Liu J; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 Mar; 21(1):223. PubMed ID: 33663447
[TBL] [Abstract][Full Text] [Related]
17. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.
Fabi A; Alesini D; Valle E; Moscetti L; Caputo R; Caruso M; Carbognin L; Ciccarese M; La Verde N; Arpino G; Cannita K; Paris I; Santini D; Montemurro F; Russillo M; Ferretti G; Filippelli G; Rossello R; Fabbri A; Zambelli A; Leonardi V; D'Ottavio AM; Nisticò C; Stani S; Giampaglia M; Scandurra G; Catania G; Malaguti P; Giannarelli D; Cognetti F
Breast; 2018 Oct; 41():137-143. PubMed ID: 30092500
[TBL] [Abstract][Full Text] [Related]
18. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4.
Stumpf PK; Cittelly DM; Robin TP; Carlson JA; Stuhr KA; Contreras-Zarate MJ; Lai S; Ormond DR; Rusthoven CG; Gaspar LE; Rabinovitch R; Kavanagh BD; Liu A; Diamond JR; Kabos P; Fisher CM
Clin Cancer Res; 2019 Jul; 25(13):3946-3953. PubMed ID: 30940654
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab emtansine: a game changer in HER2-positive early breast cancer.
Mano M
Future Oncol; 2020 Nov; 16(32):2595-2609. PubMed ID: 32734779
[TBL] [Abstract][Full Text] [Related]
20. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
